~~<i id='9370DF5CCC'><strike id='9370DF5CCC'><tt id='9370DF5CCC'><pre id='9370DF5CCC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：fashion 2025-09-08 11:05:21 - browse：513

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Choosing scientific sides in the fight against Alzheimer's

knowledge

hotspot

focus

hotspot

focus

hotspot

AdobeIfthepastyearwasprelude,theU.S.governmentin2024ispoisedtore-writetherulessurroundingtheuseofart

WSS

Bernie Sanders gets little from pharma CEOs on drug prices

Sage's campaign to raise awareness of postpartum depression hits a nerve

Having children helps parents live longer, especially after age 80

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Too many hospitalized Covid

The painfully weak evidence on taking collagen to treat arthritis

hotspot

focus

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

How one medical school became remarkably diverse

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

23andMe had bad news about my health. I wish a person had delivered it

Ebola vaccine can save some who are already sick, per new study

Psychedelics group wrestles with new pharma identity

Wegovy cuts risk of cardiovascular events by 20%, study finds

Malaria cases in Florida and Texas: Here’s what you need to know

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

hotspot

Why don't Americans have at

Germany receives 178 compensation applications from gay servicepeople over discrimination

The painfully weak evidence on taking collagen to treat arthritis

Former Georgia lieutenant governor says he received grand jury subpoena

Discs beat pads, tampons for heavy menstrual flow, new study shows

Ebola vaccine can save some who are already sick, per new study

focus

hotspot

focus

hotspot